Dear editor,

We thank Drs. Balestrino and Adriano for their insightful comments on our publication about the effects of AGAT- and GAMT-deficiency in simvastatin-induced myopathy (Balestrino and Adriano [@CR3]). Among all our findings, Balestrino and Adriano point out the increased vulnerability of simvastatin induced myopathy in AGAT-deficient (AGAT^−/−^) mice compared with wildtype and GAMT-deficient (GAMT^−/−^) mice (Sasani et al. [@CR8]). AGAT^−/−^ mice are devoid of creatine, homoarginine and guanidinoacetate---the only known products of the AGAT and GAMT pathway.

First, we have shown that creatine reduces simvastatin-induced muscle damage in creatine-deficient AGAT^−/−^ mice. This finding in mice is in line with their and other previous work in patients (Balestrino and Adriano [@CR2]; Shewmon and Craig [@CR11]). In mice, we have shown that creatine-deficient AGAT^−/−^ and GAMT^−/−^ mice reveal a severe myopathy and reduced muscle strength (Nabuurs et al. [@CR7]; Schmidt et al. [@CR9]). Therefore, creatine possesses a protective potential to ameliorate statin-induced myopathy in humans and mice.

Second, homoarginine was studied in statin-induced myopathy, given that we were the first to show that AGAT is mandatory for homoarginine synthesis in mice and humans (Choe et al. [@CR4]). However, our current experiments revealed that homoarginine supplementation in homoarginine-deficient AGAT^−/−^ mice did not affect simvastatin-induced myopathy, which is in contrast to homoarginine's role in cerebrovascular and cardiac function (Choe et al. [@CR4]; Faller et al. [@CR5]). In mouse models of ischemic stroke and heart failure, homoarginine---but not creatine---was able to improve cerebrovascular damage and normalize cardiac dysfunction in AGAT-deficient mice. We agree with Balestrino and Adriano that although we hypothesized a protective effect of homoarginine in statin-induced myopathy, we did not find any.

The third product of AGAT activity is guanidinoacetate. GAMT-deficient mice are devoid of creatine---as AGAT-deficient mice, but have increased AGAT expression and, therefore, higher guanidinoacetate levels. Therefore, Balestrino and Adriano hypothesized that the milder phenotype of GAMT- versus AGAT-deficient mice might rather be explained by elevated guanidinoacetate levels and not AGAT expression itself. Early studies with GAMT-deficient mice and patients revealed that guanidinoacetate can also be phosphorylated in the absence of creatine to partially substitute for phosphocreatine (Kan et al. [@CR6]; Schulze et al. [@CR10]). However, enzyme kinetics and recovery rates after depletion of phospho-guanidinoacetate are considerably slower compared to phosphocreatine. Phospho-guanidinoacetate is not able to fully compensate for the lack of phosphocreatine, because GAMT-deficient mice reveal a reduced muscle strength and histological signs of myopathy (Schmidt et al. [@CR9]). Moreover, in addition to AGAT- and GAMT-deficient mice, we also used wild-type controls in our experiments with normal creatine, normal homoarginine and normal guanidinoacetate levels (Sasani et al. [@CR8]). Interestingly, statin-induced muscle damage and dysfunction showed a trend to be less pronounced in GAMT-deficient mice compared with wild-type mice. Although phospho-guanidinoacetate cannot completely explain the milder phenotype of GAMT-deficient mice, (phosho) guanidinoacetate might contribute to ameliorate statin-induced myopathy in GAMT-deficient mice compared with AGAT-deficient mice as suggested by Balestrino and Adriano (Balestrino and Adriano [@CR3]). In addition to their protective roles as energy buffers, (phospho) guanidinoacetate might have similar pleitropic effects as (phospho) creatine (Wallimann et al. [@CR12]), such as being an osmolyte that protects muscle against exercise-induced hypertonic stress (Alfieri et al. [@CR1]). Finally, we agree with Balestino and Adriano that AGAT metabolites should further be evaluated as potential treatments in statin-induced myopathy.
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